Santen plans to break into the U.S. glaucoma market in 2020 with the introduction of the DE-128 microshunt, according to a speaker at the 38th annual J.P. Morgan Healthcare Conference.
“Glaucoma is one of the leading causes for blindness in many developed countries, including the United States, and we can only slow down its progression by decreasing intraocular pressure using eye drops basically until the end of life,” Shigeo Taniuchi, president and chief operating officer of Santen, said. “There is clearly an unmet medical need to deal with severe glaucoma (Read more...)
Uncategorized